Limits...
The Clinical Significance of MiR-429 as a Predictive Biomarker in Colorectal Cancer Patients Receiving 5-Fluorouracil Treatment

View Article: PubMed Central - PubMed

ABSTRACT

Background: 5-Fluorouracil (5-FU) based treatment is the standard therapy for metastatic colorectal cancer (CRC), but the development of chemoresistance is inevitable. Increasing evidence shows that dysregulation of microRNAs (miRNAs) is involved in malignant transformation. Thus, it is imperative that we find new diagnostic and prognostic marker for chemotherapy in CRC.

Material/methods: For clinical parameter analysis, 78 CRC tissues and adjacent normal tissues and 45 serum specimens from CRC patients were included in this study. For chemo-response analysis, 116 primary tissues were collected from the patients receiving first-line 5-FU treatment. Quantitative Real-Time PCR (qRT-PCR) was used to detect microRNAs expression.

Results: The expression of miR-429 was significantly increased in both serum and primary tissues from CRC patients, and enhanced miR-429 level was associated with tumor size, lymph node metastasis, and TNM stage. The diagnostic and prognostic values were also confirmed in CRC by using primary tissues. For patients receiving 5-FU-based treatment, miR-429 levels were significantly lower in responding group. The proportions of patients that did not experience response to therapy were higher in primary tumors with high miR-429 expression levels as compared with primary tumors with low miR-429 expression levels. Finally, Kaplan-Meier survival analysis showed that miR-429 is an independent prognostic indicator for chemo-response to 5-FU therapy among CRC patients.

Conclusions: High level of miR-429 expression was correlated with enhanced malignant potential and poor prognosis of CRC patients. Furthermore, miR-429 could affect the chemo-sensitivity of CRC patients to 5-FU therapy and was associated with poor response to 5-FU-based chemotherapy in patients with CRC.

No MeSH data available.


MiR-429 expression was significantly increased in CRC serum and primary tissues. (A) miR-429 expression was significantly increased in CRC primary tissues compared with adjacent normal tissues. (B) 60.3% (47 of 78) cases had at least 2-fold higher expression of miR-429 in the CRC tissues compared with adjacent normal tissues. (C) The expression of miR-429 was significantly increased in serum of CRC patients compared with healthy individuals.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC5036382&req=5

f1-medscimonit-22-3352: MiR-429 expression was significantly increased in CRC serum and primary tissues. (A) miR-429 expression was significantly increased in CRC primary tissues compared with adjacent normal tissues. (B) 60.3% (47 of 78) cases had at least 2-fold higher expression of miR-429 in the CRC tissues compared with adjacent normal tissues. (C) The expression of miR-429 was significantly increased in serum of CRC patients compared with healthy individuals.

Mentions: Seventy-eight patients who provide primary tissue samples were enrolled in this study. Among these patients, there were 49 males and 29 females; 35 patients were older than 60 years of age, and 43 patients were younger than 60 years of age with the median age of 56 years old, range (31–79 years). According to the seventh edition of the tumor node metastasis (TNM) staging criteria of CRC, 8 cases were considered stage I, 34 cases were stage II, 29 cases were stage III, and 7 cases were stage IV. qRT-PCR was used to examine the miR-429 levels in 78 cancerous and paired noncancerous tissues, and our results indicated that the expression of miR-429 was significantly increased in tumor tissues compared with paired normal tissues (p<0.001, Figure 1A). Moreover, the miR-429 expression in 60.3% (47 of 78) cases were 2-fold higher than in adjacent tissues (Figure 1B).


The Clinical Significance of MiR-429 as a Predictive Biomarker in Colorectal Cancer Patients Receiving 5-Fluorouracil Treatment
MiR-429 expression was significantly increased in CRC serum and primary tissues. (A) miR-429 expression was significantly increased in CRC primary tissues compared with adjacent normal tissues. (B) 60.3% (47 of 78) cases had at least 2-fold higher expression of miR-429 in the CRC tissues compared with adjacent normal tissues. (C) The expression of miR-429 was significantly increased in serum of CRC patients compared with healthy individuals.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC5036382&req=5

f1-medscimonit-22-3352: MiR-429 expression was significantly increased in CRC serum and primary tissues. (A) miR-429 expression was significantly increased in CRC primary tissues compared with adjacent normal tissues. (B) 60.3% (47 of 78) cases had at least 2-fold higher expression of miR-429 in the CRC tissues compared with adjacent normal tissues. (C) The expression of miR-429 was significantly increased in serum of CRC patients compared with healthy individuals.
Mentions: Seventy-eight patients who provide primary tissue samples were enrolled in this study. Among these patients, there were 49 males and 29 females; 35 patients were older than 60 years of age, and 43 patients were younger than 60 years of age with the median age of 56 years old, range (31–79 years). According to the seventh edition of the tumor node metastasis (TNM) staging criteria of CRC, 8 cases were considered stage I, 34 cases were stage II, 29 cases were stage III, and 7 cases were stage IV. qRT-PCR was used to examine the miR-429 levels in 78 cancerous and paired noncancerous tissues, and our results indicated that the expression of miR-429 was significantly increased in tumor tissues compared with paired normal tissues (p<0.001, Figure 1A). Moreover, the miR-429 expression in 60.3% (47 of 78) cases were 2-fold higher than in adjacent tissues (Figure 1B).

View Article: PubMed Central - PubMed

ABSTRACT

Background: 5-Fluorouracil (5-FU) based treatment is the standard therapy for metastatic colorectal cancer (CRC), but the development of chemoresistance is inevitable. Increasing evidence shows that dysregulation of microRNAs (miRNAs) is involved in malignant transformation. Thus, it is imperative that we find new diagnostic and prognostic marker for chemotherapy in CRC.

Material/methods: For clinical parameter analysis, 78 CRC tissues and adjacent normal tissues and 45 serum specimens from CRC patients were included in this study. For chemo-response analysis, 116 primary tissues were collected from the patients receiving first-line 5-FU treatment. Quantitative Real-Time PCR (qRT-PCR) was used to detect microRNAs expression.

Results: The expression of miR-429 was significantly increased in both serum and primary tissues from CRC patients, and enhanced miR-429 level was associated with tumor size, lymph node metastasis, and TNM stage. The diagnostic and prognostic values were also confirmed in CRC by using primary tissues. For patients receiving 5-FU-based treatment, miR-429 levels were significantly lower in responding group. The proportions of patients that did not experience response to therapy were higher in primary tumors with high miR-429 expression levels as compared with primary tumors with low miR-429 expression levels. Finally, Kaplan-Meier survival analysis showed that miR-429 is an independent prognostic indicator for chemo-response to 5-FU therapy among CRC patients.

Conclusions: High level of miR-429 expression was correlated with enhanced malignant potential and poor prognosis of CRC patients. Furthermore, miR-429 could affect the chemo-sensitivity of CRC patients to 5-FU therapy and was associated with poor response to 5-FU-based chemotherapy in patients with CRC.

No MeSH data available.